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Rampant, irrational and unscientific use of antimicrobials by the healthcare practitioners is adding 
to the problem of antimicrobial resistance. Therefore, it is of utmost importance to evolve and 
implement new policies, recommence research actions and pursue steps to manage the crisis 
of antimicrobial resistance, which can be accomplished by a well-designed Antimicrobial 
Stewardship programme. A prospective observational study aiming to investigate the use of 
antimicrobials in Intensive Care Units by means of an AMS programme was carried out in a 400 
bedded tertiary level hospital in New Delhi with 140 ICU beds. This evidence-based study looks 
into the prescription and consumption of antimicrobials, specifically in the ICUs, and attempts 
to corelate it with the resistance pattern of antimicrobials being used. All the patients being 
treated with antimicrobials, admitted in the ICUs of the hospital were selected for this descriptive 
research. Information associated with antimicrobials including the susceptibility pattern of isolates 
and full dosage regime of each patient from the group was obtained by conducting daily audits 
for a period of five months. Among the usage of different antimicrobial categories (antibacterial, 
antifungal and antiviral), the resistance percentage correlation was predominantly focused on the 
antibacterial. However, the study suggests no conclusive direct or indirect correlation between the 
usage of an antibacterial (in terms of prescription and consumption) and its resistance, which itself 
could be a cause of concern for medical practitioners.
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1. Introduction
From the time when first antibiotic, Penicillin, was 
discovered in 1928 by Alexander Fleming, there had been 
detection and recognition of antimicrobial resistance 
(AMR) (Antibiotic / Antimicrobial Resistance, CDC). 
World Health Organization (WHO) describes AMR as 
“the ability of a microorganism to stop an antimicrobial from 
working against it” ensuing ineptness of usual treatments 
(Antimicrobial Resistance, WHO). In effect, microorganisms 
will constantly attempt to tolerate new antimicrobials and 
share their resistance amongst other microorganisms, which 
possibly will further result in persistence of infections and 
dispersal to others (Antibiotic / Antimicrobial Resistance, 
CDC). Due to this, AMR has become a chief concern in 
the public health sector, resulting in prodigious loss of 
lives and capital (Laxminarayan, 2014). In developing 
countries like India, there are disproportionately higher 
occurrences of inapt antimicrobial usage and greater 
levels of resistance when equated to developed countries 
(Lim, 2016). Resistant strains of microorganisms are 
cumulating at a distressing degree, yet there is a derisory 
development of new antimicrobials. Progression of AMR 
is further encouraged by redundant and irrational usage of 
antimicrobials in healthcare institutions. Thus, there is a 
tenacious requirement for coordinated efforts to implement 
new policies, recommence research exertions and pursue 
steps to manage the crisis of AMR (Spellberg, 2014), which 
can be accomplished to some extent by a well-designed 
Antimicrobial Stewardship (AMS) programme.
According to WHO, AMS refers to “interventions designed 
to promote the optimal use of antibiotic agents, including 
drug choice, dosing, route, and duration of administration” 
(Antimicrobial Stewardship: A competency-based approach, 
WHO). The aim of this research is to investigate the use 
of antimicrobials in Intensive Care Units (ICUs) by means 
of an AMS programme. Hypothesis for the purpose of this 
research is – “the resistance percentage of an antimicrobial 
is inversely proportional to the number of times it is 
prescribed by the doctors in the hospital”. This evidence-
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based study looks into the prescription and consumption 
of antimicrobials specifically in the ICUs and attempts 
to corelate it with the resistance pattern of antibacterial 
being used. The study discloses the quantity (in grams) of 
antimicrobial prescribed in the ICUs by substantial universal 
measures, which includes Defined Daily Dose (DDD) and 
Days of Therapy (DOT). It also focuses on antimicrobial 
prescription pattern of healthcare doctors, including 
empirical therapy used. WHO Collaborating Centre for 
Drug Statistics Methodology defines DDD as “the assumed 
average maintenance dose per day for a drug used for its main 
indication in adults”. DDD essentially does not suggest the 
therapeutic dose for individual patients due to differences in 
their pharmacokinetic traits and severity of the ailment. It is 
purely used as a measurement unit (Definition and general 
Considerations – WHOCC, 2018). Another important 
unit of measurement is DOT. It refers to “the number of days 




This is a prospective observational research study carried 
out in the ICUs of a Joint Commission International 
(JCI) and National Accreditation Board for Hospitals and 
Healthcare Providers (NABH) accredited 400 bedded 
tertiary level hospital in New Delhi (India). Population 
chosen for this study included all the patients being treated 
with antimicrobials, who were admitted in the Medical 
ICU, Pediatric ICU, Cardiac ICU and Neurological ICU of 
the hospital. Prior approval was obtained from the Ethical 
Committee of the host institution and identity of patients 
and treating physician was not disclosed in the study for 
confidential reasons. 
2.2 Data Collection
Data was collected from August 2018 till December 
2018 by conducting systematic daily audits using Google 
Forms. The data was extracted from patient’s Medication 
Administration Records (MAR), progress notes, patient 
transfer records, Hospital Management System (HMS), 
hospital antibiogram and “Justification Form for Restricted 
Antimicrobials”. 
To ensure the prudent use of antimicrobials and reduce 
the risk of spreading resistance amongst antimicrobial 
agents, host institution’s drug formulary designated fifteen 
antimicrobial agents (including meropenem, imipenem, 
ertapenem, doripenem, vancomycin, linezolid, colistimethate 
sodium, tigecycline, amphotericin B, voriconazole, 
teicoplanin, polymyxin B, caspofungin, fosfomycin and 
minocyclineas) as ‘Restricted Antimicrobials’. To observe 
and regulate the consumption of ‘Restricted Antimicrobials’, 
a ‘Justification Form for Restricted Antimicrobials’ (J.F.) 
was created in 2016, as a “pre-prescription approach”. 
Antimicrobial prescribing staff was required to fill the J.F. 
prior to prescribing any restricted antimicrobial, along with 
justification. Signatures of the prescribing doctor, nursing in 
charge, a microbiologist and a clinical pharmacist were also 
required on the form. 
Information obtained for this study included 
demographic profile of the patient, primary diagnosis, initial 
antimicrobials being administered to the patient, full dosage 
regime (including, dosage form, dose, route of administration 
and frequency), duration of the antimicrobial treatment, 
change in antimicrobial prescription during the stay in 
the hospital, whether the antimicrobial being prescribed is 
restricted or not, compliance with the ‘Justification Form for 
Restricted Antimicrobials’, antimicrobial resistance pattern, 
duration of patient’s stay and clinical outcome of the patient.
2.3 Data Analysis
The data collected was retrieved from google spreadsheet 
and saved as Microsoft Excel file. Collected data was further 
summarized and analysed using Pivot Table. Electronic 
figures and graphs of analysed data were created using 
‘Charts’ feature of Excel. Descriptive statistical figures were 
expressed as the mean ± standard deviation or as percentages. 
Antimicrobial resistance pattern was obtained from 
the periodic summary of antimicrobial susceptibilities 
of local bacterial isolates, issued by the hospital’s clinical 
microbiology laboratory. For this study the phrase ‘no. 
of times prescribed’ is calculated by the total number of 
patients it has been prescribed to. The re-prescription for a 
patient has only been counted in case of change in dosage 
or root of administration of that drug. Total antimicrobial 
class consumption (in grams) was calculated by adding all 
the antimicrobial prescribed in the ICUs during the study 
period. Defined Daily Dose (DDD) per 100 bed days was 
calculated as per WHO Anatomical Therapeutic Chemical 
(ATC) classification (ATC/DDD Index, 2019), where, a bed 
day refers to ‘a day during which a person is confined to a bed 
and in which the patient stays overnight in a hospital’ (DDD 
Indicators, WHO). Average Days of Therapy (DOT) was 
also calculated, where 1 DOT is denoted by any dose of an 
antimicrobial that is received during a period of 24 hours 
(Metrics and Evaluation, Public Health Ontario).
3. Results
A total of 843 patients were evaluated for this study, out 
of which 475 (56.35%) were male and 368 (43.65%) were 
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female. 69 (8.19%) patients were 16 years old or below 
and were not considered for calculating DDDs and DOT. 
The mean age of patients was 55.48 ± 22.8. During the 
research extent 819 (97.15%) patients were admitted once, 
21 (2.49%) patients were admitted twice and 3(0.36%) 
patients were admitted thrice. 
Average duration of patient’s hospitalization was 8.77 
± 5.37 days. For this parameter, 34 patients out of the 
total 843 patients were not assessed as their duration of 
hospitalization was greater than one month and they were 
considered as outliers. Mode for 809 patients’ duration of 
hospitalization was 5 days.
3.1 Antimicrobial Consumption
Figure 1 depicts the percentage of different antimicrobial 
types used in the ICUs of the host institution. Antibacterial 
were prescribed 1631 (93.84%) times, antifungals were 
prescribed 83 (4.78%) times and antiviral were prescribed 
only 24 (1.38%) times.
Figure 1: Antimicrobials (%) Prescribed in ICUs.
The total usage of different antibacterial in the ICUs 
is portrayed in Figure 2. Among the most prescribed 
antibacterial classes, Cephalosporins ranked first at 32.86% 
followed by Penicillin at 18.70% and Carbapenems 
at 10.55%. The least prescribed antimicrobials were 
phosphonic acid derivatives and Sulfonamides at 0.06%.
Figure 3 and 4 depicts the percentage of antifungal 
and antiviral usage in ICUs respectively. The most used 
antifungal was Fluconazole at 70%, while the most used 
antiviral was Oseltamivir at 54%.
50% of the total patients were administered with a 
maximum of one antimicrobial at a time, 31% patients 
received 2 antimicrobials at a time, 13% patients received 
3 and 6% patients were administered with 4 or more 
antimicrobials at a time, as shown in Figure 5.
Figure 2: Antibacterial Usage (%) in ICUs
Figure 3: Antifungal Usage (%) in ICUs
Figure 4: Antiviral Usage (%) in ICUs
Figure 5: Maximum Antimicrobials Given at a Time
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Figure 6 shows the total number of antimicrobials prescribed 
to a patient during their course of stay in the hospital. 372 
patients were prescribed with only a single antimicrobial, 260 
patients were prescribed with 2 antimicrobials, 114 patients 
with 3 antimicrobials, 54 patients with 4 antimicrobials and 
43 patients were prescribed with 5 or more antimicrobials.
Figure 6: Total Number of Antimicrobials Prescribed to a Patient
3.2 Restricted Antimicrobials
238 (28.23%) ICU patients were prescribed the ‘Restricted 
Antimicrobials’, while 605 (71.77%) patients were not. 
Figure 7 shows the usage of Restricted Antimicrobials in 
the ICUs in percentage. Meropenem was the most used 
Restricted Antimicrobials at 44.72% followed by Teicoplanin 
at 23.33% and Colistin at 12.50%.
Figure 7: Restricted Antimicrobial Usage (%)
Figure 8: Compliance with ‘Justification Form for Restricted 
Antimicrobials’ (J.F.)
Figure 8 portrays that of all the 28% patients prescribed with 
‘Restricted Antimicrobials’, J.F. was filled for 64.75% patients as 
per the hospital’s guidelines and not filled for 8.19% patients. 
During the audits, it was also observed that J.F. was missing from 
the medical files of 27.04% ICU patients.
















Acyclovir 65.70 4 16.43 2.12
Amikacin 246.15 1 246.15 31.80
Amoxicillin (IV) 3179.30 3 1059.77 136.92
Amoxicillin (Oral) 71.25 1.5 47.50 6.14
Amphotericin B 0.35 0.035 10.00 1.29
Azithromycin (IV) 9.00 0.5 18.00 2.33
Azithromycin 
(Oral)
28.70 0.3 95.67 12.36
Aztreonam 83.00 4 20.75 2.68
Cefepime 1314.80 4 328.70 42.47
Cefipirome 1929.00 4 482.25 62.31
Cefoperazone 88.00 4 22.00 2.84
Cefotaxime 59.00 4 14.75 1.91
Cefpodoxime 
(Oral)
3.60 0.4 9.00 1.16
Ceftazidime 355.88 4 88.97 11.49
Ceftriaxone 5800.00 2 2900.00 374.68
Cefuroxime (IV) 183.00 3 61.00 7.88
Cefuroxime (Oral) 62.00 0.5 124.00 16.02
Cefuroxime + 
Sulbactum
724.50 3 241.50 31.20
Ciprofloxacin (IV) 37.80 0.8 47.25 6.10
Ciprofloxacin 
(Oral)
10.00 1 10.00 1.29
Clarithromycin 
(IV)
304.12 1 304.12 39.29
Clarithromycin 
(Oral)
288.90 0.5 577.80 74.65
Clindamycin (IV) 336.90 1.8 187.17 24.18
Clindamycin 
(Oral)
14.40 1.2 12.00 1.55
Colistimethate 
Sodium
37.76 0.96 39.33 5.08
Colistin 106.32 0.96 110.75 14.31
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Doxycycline (IV) 84.90 0.1 849.00 109.69
Doxycycline 
(Oral)
17.20 0.1 172.00 22.22
Ertapenem 18.00 1 18.00 2.33
Flucloxacillin 111.00 2 55.50 7.17
Fluconazole (IV) 132.80 0.2 664.00 85.79
Fluconazole 
(Oral)
33.15 0.2 165.75 21.41
Fosfomycin 132.00 8 16.50 2.13
Imipenem 138.00 2 69.00 8.91
Levofloxacine 77.50 0.5 155.00 20.03
Linezolid (IV) 269.40 1.2 224.50 29.01
Linezolid (Oral) 120.00 1.2 100.00 12.92
Meropenem 3446.45 3 1148.82 148.43
Metronidazole 
(IV)
1884.05 1.5 1256.03 162.28
Metronidazole 
(Oral)
24.00 2 12.00 1.55
Minocycline 0.80 0.2 4.00 0.52
Moxifloxacine 14.80 0.2 74.00 9.56
Ofloxacin 18.00 0.4 45.00 5.81
Ornidazole 23.00 1 23.00 2.97
Oseltamivir (Oral) 11.55 0.15 77.00 9.95
Piperacillin 12676.50 14 905.46 116.99
Polymixin B 19.30 0.15 128.67 16.62
Streptomycin 11.00 1 11.00 1.42
Teicoplanin 269.00 0.4 672.50 86.89
Ticarcillin 414.20 15 27.61 3.57
Tigecycline 2.90 0.1 29.00 3.75
Tobramycin (IV) 0.45 0.24 1.88 0.24
Tobramycin 
(Inhalation)
20.40 0.3 68.00 8.79
Trimethoprim / 
sulfamethoxazole
3.84 0.2 19.20 2.48
Vancomycin 84.29 2 42.15 5.45
Voriconazole (IV) 12.60 0.4 31.50 4.07
Voriconazole 
(Oral)
80.60 0.4 201.50 26.03
3.3 Defined Daily Dose (DDD)
Total number of adult patients evaluated for this study were 
774 excluding 69 pediatric patients and total number of adult 
patient bed days were 8170. The DDD per 100 bed days of 
every antimicrobial prescribed in the ICUs during the study 
period, is depicted in Table 1. The highest DDD/100 bed 
days was of ceftriaxone at 374.68 DDDs, whereas lowest was 
of tobramycin (Intravenous – IV) at 0.24 DDDs.
3.4 Resistance Percentage of Antimicrobial 
corresponding to Usage Variables
Table 2 lays down the details of the most used antimicrobials in 
the ICU in relation to their resistance percentage, prescription, 
along with their average DOT. Here, 100 resistance percentage 
of an antimicrobial means that all the microorganisms isolated 
from the various clinical samples were resistant to that 
particular antimicrobial. While, 0 resistance percentage of 
an antimicrobial indicates that none of the microorganisms 
isolated were resistant to that specific antimicrobial. The 
isolates obtained were tested for antimicrobial susceptibility 
using Vitek 2 systems, as per the Clinical and Laboratory 
Standards Institute (CLSI) guidelines. 













Amikacin 51.00 40 311 7.78
Amoxicillin 75.38 182 1054 5.79
Azithromycin 0.00 21 100 4.76
Aztreonam 98.00 2 18 9.00
Cefepime 67.53 34 343 10.09
Cefixime 0.00 1 2 2.00
Cefoperazone 61.20 4 27 6.75
Cefotaxime 92.00 6 28 4.67
Ceftazidime 71.83 14 116 8.29
Ceftriaxone 76.43 384 2626 6.84
Cefuroxime 91.75 14 134 9.57
Ciprofloxacin 82.10 9 79 8.78
Clindamycin 75.50 39 307 7.87
Colistin 0.00 37 352 9.51
Ertapenem 53.38 2 18 9.00
Imipenem 57.07 9 92 10.22
Linezolid 0.00 32 362 11.31
Meropenem 58.07 161 1472 9.14
Minocycline 100.00 1 4 4.00
Piperacillin 77.13 117 1213 10.37
Ticarcillin 92.25 3 57 19.00
Tigecycline 59.50 4 38 9.50
Vancomycin 0.00 11 111 10.09
3.5 Clinical Outcome of Patients
As revealed in Figure 9, out of the total population 725 
(86%) patients were discharged from the hospital, while 
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118 (14%) patients expired. Data of discharged patients also 
include patients that left the hospital against the medical 
advice (LAMA patients).
Figure 9: Clinical Outcome (%) of the Patient
4. Discussion
This investigation is predominantly focused on the ICUs 
because ICUs are the most frequently identified source of 
resistant strains and hospital acquired infections (HAI) with 
several fold higher infection rates than general hospital wards 
(Jamshidi, 2009). Hence probing the ICUs will provide a 
comprehensive spectrum of resistance patterns and also 
the problems generated by it. Assessment of antimicrobial 
utilization pattern in ICUs is vital since it contributes to 
rational use of antimicrobials by distinguishing initial signs 
of unreasonable use of antimicrobial and it further helps 
to recognize appropriate interventions that are needed 
(Marschner, 1994).
The average days a patient was admitted in the hospital 
were 8.77 ± 5.37. This length of stay was reasonable for 
ICUs’ patients when compared to other research studies 
(Sulieman, 2018) (Merzougui, 2018). Patients suffering 
from cardiovascular, nervous, cerebrovascular or multiple 
diseases usually have significantly higher length of stay. 
(Toptas, 2018).
All in all, the consumption of the antimicrobial, 
Cephalosporin was the highest among the antibacterial 
being used. Cephalosporin is a beta-lactam antibiotic, 
which is lethal to both gram positive and gram-negative 
bacteria, also including anaerobic (Penicillins, 2000). 
Such a high use of Cephalosporins might be due to the 
facts that it actions against a broad range of organisms, it 
is easy to endure, it can be administered effortlessly and 
it does not cost much (Alyssa, 2018). 50% of the ICU 
patients were treated with a single antimicrobial while 50% 
patients received multiple antimicrobial therapy. Multiple 
therapy prescription relies upon the type of infection and 
its severity. Multiple therapy might also be used in view of 
pharmacodynamic properties of antimicrobials, specifically 
synergetic and additive effect. For instance, colistin is used 
in combination with other antimicrobials like rifampin, 
β-lactams or glycopeptides, as it attributes therapeutic 
benefit against colistin resistant Acinetobacter baumannii 
(Bae, 2016).
Population of resistant pathogenic microorganisms can 
easily be computed by the antimicrobial consumption data 
for the reason that the consumption of antimicrobials is 
directly proportional to the progression of AMR (Sharma, 
2010). Consequently, it is crucial to regulate the use of 
antimicrobials to reduce the risk of resistance amongst 
microorganisms (Austin, 1999). Correspondingly, influence 
of supervisory interferences and educational exercises can 
straightforwardly be assessed by such data. 
DDD has been used as an additional benchmark of 
antimicrobial consumption. While DOT can be used as 
an additional data point for cross-referencing prescription. 
Calculating DDDs is extremely common and convenient 
technique to illustrate the over-all consumption of antimicrobials, 
for the reason that it authorizes equating therapeutic disparities 
at international, national and institutional level (Surveillance 
of Antimicrobial Use, WHO). Such comparisons lead to create 
cognizance among healthcare practitioners and allows them 
to identify their global position in the battle against AMR. 
It also permits them to incorporate improved and stringent 
healthcare policies and guidelines, which further assist in this 
fight.
Drawing from the hypothesis, according to these 
data points, derived in the research, there seems to be 
no overarching direct or indirect correlation between 
the variables because in certain cases (like piperacillin, 
ceftriaxone and amoxicillin), the prescription is high 
despite the resistance percentage being high. But in 
more than 50% cases, the correlation is indirect and the 
prescription number is low in instances of high percentage of 
resistance, like in cases of minocycline, aztreonam, ticarcillin 
and cefotaxime. 
5. Limitations
Although the researcher tried to be as thorough in the study 
as possible, but there were few limitations that did not allow 
the study to reach its full potential. First and foremost, in 
the existing literature and the research studies available on 
the issue, direct comparison with this study was not possible 
because the attributes of the variables in this study were 
not found anywhere else. Also, being from biotechnology 
background, the skill set and knowledge base of the 
researcher in terms of clinically expertise was limited and 
thus in-depth clinical correlation could not be established 
among variables
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Conclusion
This research study, conducted in a tertiary level hospital in 
Delhi provided a summative and illustrated representation 
of the antimicrobial data collected of 843 patients. The 
correlations presented in this report included number 
crunching, drawing parallels and proportionality among 
various variable related to antimicrobial consumption in the 
ICUs. Drawing from these, the core purpose of the research 
was to find the correlation between the resistance percentage 
of the relevant antimicrobials and their corresponding usage 
among the entire data set.
The research was the first of its kind in the context of 
Delhi with regard to any hospital of this scale and size. The 
quantum of data collected for the purpose of this study is 
also unprecedented. The study revealed that cephalosporin 
class had maximum consumption (32.86%) among different 
antibacterial drugs, fluconazole was the most consumed 
antifungal (70%), while the most used antiviral was 
oseltamivir (54%). Among cephalosporins, cefixime had the 
lowest resistant percentage (0%). Other cephalosporins like 
cefepime, cephoperazone and ceftazidime had the resistance 
percentage of 67.53%, 61.20%, and 71.83% respectively. 
A few other antimicrobials, which displayed zero resistance 
percentage were colistin, vancomycin and azithromycin.
Although drug resistance percentage is not the only 
factor influencing a drug prescription, as was confirmed 
by further discussions and consultations with the doctors 
and pharmacists. Issues like severity of infection, primary 
diagnosis, combination with other medicines also play a 
major role in prompting the doctor to prescribe a particular 
drug. But still it plays a crucial role, ignoring which might 
led to severe consequences.
The continued and extended use of these drugs with high 
resistance percentage might lead to increased development 
of MDRO which might further result in worse health 
conditions and high mortality rate, from where there is no 
turning back. Furthermore, treatment and management 
of patients with MDR is extremely complex for medical, 
and social facilities available to us. Also, the public health 
system in our country isn’t equipped or developed enough 
to handle the issues of this complexity.
Even though there seems to be no conclusive direct 
or indirect correlation between the usage of a medicine 
(in terms of prescription and consumption) and its 
resistance. But the fact that there is no indirect correlation 
and the resistance percentage has no sustained impact on 
the prescription pattern, itself is a cause of concern, in 
medicine. The basic understanding of these concepts would 
lead everyone to the same conclusion, there should be an 
influence of the resistance a medicine has on its prescription 
and usage. The lack of this influence becomes a major point 
of intervention for medical practitioners. The foremost 
recommendation based on this result would be to keep the 
antibiogram or resistance percentage of any drug in mind 
before the prescription of that particular drug, especially in 
cases of prolonged dosage.
Notes
Financial Support – Nil
Conflicts of Interest – None Declared
References
Alyssa, R. (2018). Cephalosporins. UpToDate Website: 
https://www.uptodate.com/contents/cephalosporins 
Antibiotic / Antimicrobial Resistance (AR / AMR), Centers 
for Disease Control and Prevention Website:
 https://www.cdc.gov/drugresistance/about.html
Antimicrobial Resistance, World Health Organization Website: 
https://www.who.int/antimicrobial-resistance/en/
Antimicrobial Stewardship: A competency-based approach, 
World Health Organization Website: 
 https://openwho.org/courses/AMR-competency
ATC/DDD Index 2019,  WHO Collaborating Centre for 
Drug Statistics Methodology Website:
 http://www.whocc.no/atcddd/
Austin, D. J., Kristinsson, K. G., & Anderson, R. M. 
(1999). The relationship between the volume of 
antimicrobial consumption in human communities 
and the frequency of resistance.  Proceedings of the 
National Academy of Sciences, 96(3), 1152–1156.
 https://doi.org/10.1073/pnas.96.3.1152
Bae, S., Kim, M. C., Park, S. J., Kim, H. S., Sung, H., Kim, 
M. N., ... & Kim, Y. S. (2016). In vitro synergistic 
activity of antimicrobial agents in combination 
against clinical isolates of colistin-resistant 
Acinetobacterbaumannii.  Antimicrobial agents and 
chemotherapy, AAC-00839. DOI:
 https://dx.doi.org/10.1128%2FAAC.00839-16
DDD Indicators, World Health Organization Website: 
ht tps : / /www.who. int/medic ines/ regula t ion/
medicines-safety/toolkit_indicators/en/
Definition and General Considerations, WHO 
Collaborating Centre for Drug Statistics Methodology 
Website: www.whocc.no/ddd/definition_and_
general_considera/
Griffith, M., Postelnick, M., & Scheetz, M. (2012). 
Antimicrobial stewardship programs: methods of 
operation and suggested outcomes. Expert review of 
anti-infective therapy, 10(1), 63–73.
 https://doi.org/10.1586/eri.11.153
ISSN No.: 2393-8536 (Print) ISSN No.: 2393-8544 (Online) Registration No. : CHAENG/2014/57978
J. Multidiscip Res. Healthcare Vol. 5, No. 1, October 2018 pp.32
Jamshidi, M., Javadpour, S., Eftekhari, T. E., Moradi, N., 
&Jomehpour, F. (2009). Antimicrobial resistance 
pattern among intensive care unit patients.  African 
Journal of Microbiology Research, 3(10), 590–594.
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., 
Wertheim, H. F., Sumpradit, N., ... &Greko, C. 
(2013). Antibiotic resistance—the need for global 
solutions. The Lancet infectious diseases, 13(12), 1057–
1098.
 https://doi.org/10.1016/S1473-3099(13)70318-9
Lim, C., Takahashi, E., Hongsuwan, M., Wuthiekanun, V., 
Thamlikitkul, V., Hinjoy, S., ... &Limmathurotsakul, 
D. (2016). Epidemiology and burden of multidrug-
resistant bacterial infection in a developing 
country.  Elife,  5, e18082. PDF: https://cdn.
elifesciences.org/articles/18082/elife-18082-v1.pdf
Marschner, J. P., Thürmann, P., Harder, S., &Rietbrock, N. 
(1994). Drug utilization review on a surgical intensive 
care unit. International journal of clinical pharmacology 
and therapeutics, 32(9), 447–451. PMID: 7820326
Merzougui, L., Barhoumi, T., Guizani, T., Barhoumi, H., 
Hannachi, H., Turki, E., &Majdoub, W. (2018). Les 
infections nosocomialesen milieu de réanimation: 
incidence annuelle et aspects cliniques au Service de 
RéanimationPolyvalente, Kairouan, Tunisie, 2014. The 
Pan African medical journal, 30. https://dx.doi.org/10.
11604%2Fpamj.2018.30.143.13824
Metrics and Evaluation. Public Health Ontario: https://
www.publichealthontario.ca/fr/eRepository/ASP%20
Metric%20examples.pdf
Penicillins, O. (2000). Appropriate prescribing of oral beta- 
lactam antibiotics. Am Fam Physician, 62, 611–620. 
 http://www.p-e-g.de/Research_News/10092000-6.html
Sharma, P. R., & Barman, P. (2010). Antimicrobial 
consumption and impact of “Reserve antibiotic 
indent form” in an intensive care unit.  Indian 
journal of pharmacology,  42(5), 297. https://doi.
org/10.4103/0253-7613.70216
Spellberg, B., & Gilbert, D. N. (2014). The future of antibiotics 
and resistance: a tribute to a career of leadership by 
John Bartlett.  Clinical infectious diseases,  59(suppl_2), 
S71–S75. https://doi.org/10.1093/cid/ciu392
Sulieman, H., El-Mahdi, W., Awadelkareem, M., &Nazer, 
L. (2018). Characteristics of Critically-Ill Patients at 
Two Tertiary Care Hospitals in Sudan. Sultan Qaboos 
University Medical Journal, 18(2), e190. https://dx.doi.
org/10.18295%2Fsqumj.2018.18.02.011
Surveillance of Antimicrobial Use, World Health 
Organization Website: https://www.who.int/
medicines/areas/rational_use/AMU_Surveillance/en/
Toptas, M., SengulSamanci, N., Akkoc, İ., Yucetas, E., 
Cebeci, E., Sen, O., ... & Ozturk, S. (2018). Factors 
Affecting the Length of Stay in the Intensive Care 
Unit: Our Clinical Experience.  BioMed research 
international, 2018.
 https://dx.doi.org/10.1155%2F2018%2F9438046
